In a report released yesterday, Steven Lichtman from Oppenheimer assigned a Buy rating to Medtronic (MDT), with a price target of $134.00. The company’s shares closed last Tuesday at $118.00, close to its 52-week high of $120.53.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of 17.6% and a 58.8% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Boston Scientific.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medtronic with a $130.81 average price target, representing an 11.3% upside. In a report issued on February 17, Morgan Stanley also reiterated a Buy rating on the stock with a $140.00 price target.
See today’s analyst top recommended stocks >>
Based on Medtronic’s latest earnings release for the quarter ending October 31, the company reported a quarterly revenue of $7.65 billion and net profit of $489 million. In comparison, last year the company earned revenue of $7.71 billion and had a net profit of $1.36 billion.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.
